In relation, GLP-1 receptor agonists were not approved by the FDA to be prescribed to pediatric patients for the majority of our study (liraglutide was approved in July 2019 for children with T2DM and for children with obesity in December 2020). This evidence concerns the gene GLP1R and Obesity.